173 related articles for article (PubMed ID: 22876271)
21. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats.
Adamczyk P; Miszkiel J; McCreary AC; Filip M; Papp M; Przegaliński E
Brain Res; 2012 Mar; 1444():45-54. PubMed ID: 22325096
[TBL] [Abstract][Full Text] [Related]
22. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
Asproni B; Murineddu G; Corona P; Pinna GA
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
[TBL] [Abstract][Full Text] [Related]
23. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
Silvestri R; Cascio MG; La Regina G; Piscitelli F; Lavecchia A; Brizzi A; Pasquini S; Botta M; Novellino E; Di Marzo V; Corelli F
J Med Chem; 2008 Mar; 51(6):1560-76. PubMed ID: 18293908
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Lan R; Liu Q; Fan P; Lin S; Fernando SR; McCallion D; Pertwee R; Makriyannis A
J Med Chem; 1999 Feb; 42(4):769-76. PubMed ID: 10052983
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
28. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
29. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
30. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
[TBL] [Abstract][Full Text] [Related]
31. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
Lan R; Gatley J; Lu Q; Fan P; Fernando SR; Volkow ND; Pertwee R; Makriyannis A
AAPS PharmSci; 1999; 1(2):E4. PubMed ID: 11741201
[TBL] [Abstract][Full Text] [Related]
33. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
Costa B; Giagnoni G; Franke C; Trovato AE; Colleoni M
Br J Pharmacol; 2004 Sep; 143(2):247-50. PubMed ID: 15313881
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways.
Yoshihara S; Morimoto H; Yamada Y; Abe T; Arisaka O
Am J Respir Crit Care Med; 2004 Nov; 170(9):941-6. PubMed ID: 15306537
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain.
Yoshihara S; Morimoto H; Ohori M; Yamada Y; Abe T; Arisaka O
Pharmacology; 2006; 76(4):157-62. PubMed ID: 16446560
[TBL] [Abstract][Full Text] [Related]
36. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands.
Murineddu G; Asproni B; Corona P; Piras S; Lazzari P; Ruiu S; Legnani L; Toma L; Pinna GA
Molecules; 2019 Apr; 24(9):. PubMed ID: 31035548
[TBL] [Abstract][Full Text] [Related]
37. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.
Rahn EJ; Zvonok AM; Thakur GA; Khanolkar AD; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2008 Nov; 327(2):584-91. PubMed ID: 18664590
[TBL] [Abstract][Full Text] [Related]
38. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
39. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).
Francisco ME; Seltzman HH; Gilliam AF; Mitchell RA; Rider SL; Pertwee RG; Stevenson LA; Thomas BF
J Med Chem; 2002 Jun; 45(13):2708-19. PubMed ID: 12061874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
